Compare HLN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | MIST |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | United Kingdom | Canada |
| Employees | 24524 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1B | 176.3M |
| IPO Year | N/A | 2019 |
| Metric | HLN | MIST |
|---|---|---|
| Price | $9.30 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 9.5M | 1.3M |
| Earning Date | 02-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.55 | $2,915.14 |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | $49.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $1.00 |
| 52 Week High | $11.42 | $3.06 |
| Indicator | HLN | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 33.49 |
| Support Level | $9.30 | $1.00 |
| Resistance Level | $9.50 | $2.30 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 83.84 | 3.97 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).